Drug profile · INN
polatuzumab vedotin-piiq
POLIVY
polatuzumab vedotin-piiq (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — polatuzumab vedotin-piiq
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
polatuzumab vedotin-piiq (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
B-cell antigen receptor complex-associated protein beta chain binding agent
Primary target: B-cell antigen receptor complex-associated protein beta chain
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is polatuzumab vedotin-piiq?
polatuzumab vedotin-piiq (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for polatuzumab vedotin-piiq?
POLIVY is a marketed brand name for polatuzumab vedotin-piiq. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of polatuzumab vedotin-piiq?
polatuzumab vedotin-piiq has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.